DNA methylation analysis of glioblastomas harboring FGFR3-TACC3 fusions identifies a methylation subclass with better patient survival.
作者信息
Wu Zhichao, Lopes Abath Neto Osorio, Bale Tejus A, Benhamida Jamal, Mata Douglas, Turakulov Rust, Abdullaev Zied, Marker Daniel, Ketchum Courtney, Chung Hye-Jung, Giannini Caterina, Quezado Martha, Pratt Drew, Aldape Kenneth
机构信息
Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
Department of Pathology, University of Pittsburgh Medical Center, 200 Lothrop Street, Pittsburgh, PA, 15213, USA.
出版信息
Acta Neuropathol. 2022 Jul;144(1):155-157. doi: 10.1007/s00401-022-02430-7. Epub 2022 May 14.
Abstract
摘要
相似文献
1
DNA methylation analysis of glioblastomas harboring FGFR3-TACC3 fusions identifies a methylation subclass with better patient survival.对携带FGFR3-TACC3融合基因的胶质母细胞瘤进行DNA甲基化分析，确定了一个患者生存率更高的甲基化亚类。
Acta Neuropathol. 2022 Jul;144(1):155-157. doi: 10.1007/s00401-022-02430-7. Epub 2022 May 14.
2
Can adult -wildtype glioblastomas with fusions be reliably predicted by histological features?具有融合的成人野生型胶质母细胞瘤能否通过组织学特征可靠预测？
Clin Neuropathol. 2021 May-Jun;40(3):165-167. doi: 10.5414/NP301357.
3
Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions.IDH 野生型伴 FGFR3-TACC3 融合的胶质母细胞瘤的遗传和表观遗传景观。
Acta Neuropathol Commun. 2020 Nov 9;8(1):186. doi: 10.1186/s40478-020-01058-6.
4
Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.异柠檬酸脱氢酶（IDH）野生型胶质瘤中FGFR-TACC融合蛋白的检测、特征分析及抑制作用
Clin Cancer Res. 2015 Jul 15;21(14):3307-17. doi: 10.1158/1078-0432.CCR-14-2199. Epub 2015 Jan 21.
5
Multiple functions of a glioblastoma fusion oncogene.脑胶质母细胞瘤融合癌基因的多种功能。
J Clin Invest. 2013 Feb;123(2):548-51. doi: 10.1172/JCI67658. Epub 2013 Jan 9.
6
Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with FGFR3::TACC3 fusion.具有 FGFR3::TACC3 融合的弥漫性神经胶质瘤的临床病理和表观遗传异质性。
Acta Neuropathol Commun. 2023 Jan 16;11(1):14. doi: 10.1186/s40478-023-01506-z.
7
FGFR3-TACCs3 Fusions and Their Clinical Relevance in Human Glioblastoma.成纤维细胞生长因子受体 3 融合基因及其在人胶质母细胞瘤中的临床意义。
Int J Mol Sci. 2022 Aug 4;23(15):8675. doi: 10.3390/ijms23158675.
8
Precise editing of FGFR3-TACC3 fusion genes with CRISPR-Cas13a in glioblastoma.使用 CRISPR-Cas13a 精准编辑胶质母细胞瘤中的 FGFR3-TACC3 融合基因。
Mol Ther. 2021 Nov 3;29(11):3305-3318. doi: 10.1016/j.ymthe.2021.07.002. Epub 2021 Jul 16.
9
Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients.FGFR3-TACC3融合作为EGFR突变的非小细胞肺癌患者对EGFR酪氨酸激酶抑制剂潜在的旁路耐药机制的出现。
Lung Cancer. 2017 Sep;111:61-64. doi: 10.1016/j.lungcan.2017.07.006. Epub 2017 Jul 11.
10
The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.成胶质细胞瘤中致癌性 FGFR3-TACC3 基因融合逃避 miR-99a 的调控。
J Clin Invest. 2013 Feb;123(2):855-65. doi: 10.1172/JCI67144. Epub 2013 Jan 9.
引用本文的文献
1
cIMPACT-NOW update 9: Recommendations on utilization of genome-wide DNA methylation profiling for central nervous system tumor diagnostics.cIMPACT-NOW更新9：关于全基因组DNA甲基化谱在中枢神经系统肿瘤诊断中的应用建议。
Neurooncol Adv. 2025 Jan 3;7(1):vdae228. doi: 10.1093/noajnl/vdae228. eCollection 2025 Jan-Dec.
2
Targeting Mitochondria in Glioma: New Hopes for a Cure.靶向胶质瘤中的线粒体：治愈的新希望。
Biomedicines. 2024 Nov 28;12(12):2730. doi: 10.3390/biomedicines12122730.
3
Phenotypic and epigenetic heterogeneity in FGFR2-fused glial and glioneuronal tumours.FGFR2 融合型神经胶质和神经胶质神经元肿瘤的表型和表观遗传异质性。
Neuropathol Appl Neurobiol. 2024 Dec;50(6):e13014. doi: 10.1111/nan.13014.
4
Conundrum of 3N: nasopharyngeal nonkeratinizing non-viral carcinoma-reappraisal of fusions and report of two consecutive cases with unusual molecular findings.3N难题：鼻咽非角化非病毒癌——融合基因的重新评估及两例具有异常分子发现的连续病例报告
Virchows Arch. 2025 May;486(5):1085-1090. doi: 10.1007/s00428-024-03877-7. Epub 2024 Jul 18.
5
TARGET: A phase I/II open-label multicenter study to assess safety and efficacy of fexagratinib in patients with relapsed/refractory FGFR fusion-positive glioma.目标：一项I/II期开放标签多中心研究，旨在评估非沙格拉替尼在复发/难治性FGFR融合阳性胶质瘤患者中的安全性和有效性。
Neurooncol Adv. 2024 May 20;6(1):vdae068. doi: 10.1093/noajnl/vdae068. eCollection 2024 Jan-Dec.
6
Diffuse Gliomas with :: Fusion: Morphological and Molecular Features and Classification Challenges.伴有融合的弥漫性胶质瘤：形态学和分子特征及分类挑战
Cancers (Basel). 2024 Apr 25;16(9):1644. doi: 10.3390/cancers16091644.
7
Clinicopathological and Molecular Characteristics of -Wildtype Glioblastoma with Fusion.具有融合的野生型胶质母细胞瘤的临床病理和分子特征
Biomedicines. 2024 Jan 10;12(1):150. doi: 10.3390/biomedicines12010150.
8
Diffuse Gliomas with FGFR3-TACC3 Fusions: Oncogenic Mechanisms, Hallmarks, and Therapeutic Perspectives.具有FGFR3-TACC3融合的弥漫性胶质瘤：致癌机制、特征及治疗前景
Cancers (Basel). 2023 Nov 23;15(23):5555. doi: 10.3390/cancers15235555.
9
A diffuse glioma with oligodendroglial-like cells and extensive calcifications.弥漫性胶质瘤伴少突胶质样细胞和广泛钙化。
Brain Pathol. 2024 Jan;34(1):e13187. doi: 10.1111/bpa.13187. Epub 2023 Jul 6.
10
A comprehensive analysis of infantile central nervous system tumors to improve distinctive criteria for infant-type hemispheric glioma versus desmoplastic infantile ganglioglioma/astrocytoma.全面分析婴儿中枢神经系统肿瘤，以提高婴儿型大脑半球胶质瘤与促结缔组织增生性婴儿型节细胞胶质瘤/星形细胞瘤的鉴别标准。
Brain Pathol. 2023 Sep;33(5):e13182. doi: 10.1111/bpa.13182. Epub 2023 Jun 22.
本文引用的文献
1
Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions.IDH 野生型伴 FGFR3-TACC3 融合的胶质母细胞瘤的遗传和表观遗传景观。
Acta Neuropathol Commun. 2020 Nov 9;8(1):186. doi: 10.1186/s40478-020-01058-6.
2
Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions.具有 FGFR3-TACC3 融合的神经胶质瘤的临床、分子和放射组学特征。
Neuro Oncol. 2020 Nov 26;22(11):1614-1624. doi: 10.1093/neuonc/noaa121.
3
Comparative proteogenomic characterization of glioblastoma.胶质母细胞瘤的比较蛋白质基因组学特征分析
CNS Oncol. 2019 Jun;8(2):CNS37. doi: 10.2217/cns-2019-0003. Epub 2019 Jul 10.
4
Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas.在成人脑胶质瘤中，靶向基因融合与 IDH 野生型星形细胞谱系相关。
J Neuropathol Exp Neurol. 2018 Jun 1;77(6):437-442. doi: 10.1093/jnen/nly022.
5
DNA methylation-based classification of central nervous system tumours.基于 DNA 甲基化的中枢神经系统肿瘤分类。
Nature. 2018 Mar 22;555(7697):469-474. doi: 10.1038/nature26000. Epub 2018 Mar 14.
6
A metabolic function of FGFR3-TACC3 gene fusions in cancer.成纤维细胞生长因子受体 3-转录延伸因子 3 基因融合在癌症中的代谢功能。
Nature. 2018 Jan 11;553(7687):222-227. doi: 10.1038/nature25171. Epub 2018 Jan 3.
7
Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular features.具有 FGFR3-TACC3 融合的弥漫性神经胶质瘤具有特征性的组织病理学和分子特征。
Brain Pathol. 2018 Sep;28(5):674-683. doi: 10.1111/bpa.12563. Epub 2017 Nov 21.
8
The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.成胶质细胞瘤中致癌性 FGFR3-TACC3 基因融合逃避 miR-99a 的调控。
J Clin Invest. 2013 Feb;123(2):855-65. doi: 10.1172/JCI67144. Epub 2013 Jan 9.
9
Transforming fusions of FGFR and TACC genes in human glioblastoma.人类胶质母细胞瘤中 FGFR 和 TACC 基因的融合转化。
Science. 2012 Sep 7;337(6099):1231-5. doi: 10.1126/science.1220834. Epub 2012 Jul 26.
Zotero 插件